Showing 473 results
-
Press release /Poor patients in Punjab will have access to high-quality medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will…
-
Press release /For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx® as comprehensive treatment across multiple manifestations of…
-
Press release /FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible Using patients' self-recorded measurements, FocalView aims to…
-
Ad hoc release /Basel, April 19, 2018 - Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1, 2018, and…
-
Ad hoc release /Basel, April 17, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, a Delaware corporation ("Purchaser"), has…
-
Ad hoc release /Price reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term…
-
Press release /Aktionäre genehmigen für 2017 die 21. Dividendenerhöhung in Folge auf CHF 2,80 pro Aktie (+2%) - dies entspricht einer Rendite von 3,6% und einer Ausschüttungsquote von rund 67% des Free Cashflow…
-
Press release /Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position. The…
-
Press release /Emerging evidence from first 18 months of LPEP program demonstrates operational feasibility integrating single-dose rifampicin into routine control programs in 6 countries Retrospective…
-
Press release /Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also…